LEGN Company Profile and Key Details

Q: Who are the executives of LEGN?

Ms. Liz GosenSenior Vice President of Technical OperationsDr. Ying Huang Ph.D.Chief Executive Officer & DirectorMr. Alan KickSenior Vice President of Global QualityMs. Lori A. Macomber C.P.A.Chief Financial OfficerDr. Yuhong Qiu Ph.D.Senior Vice President of Global Regulatory AffairsDr. Guowei Fang Ph.D.Senior Vice President & Global Head of Research and Early Devel.Mr. Marc HarrisonVice President & Gen. CounselMs. Lori A. Macomber CPAChief Financial OfficerMr. Steven J. GavelSenior Vice President of Commercial Devel., US & EuropeJoanne ChoiSenior Mang. of Investor RelationsMs. Elaine QianVice President & Global Head of HRDeborah WongExecutive Director of Strategic Marketing & Corporation Communications

NASDAQ : LEGN

Legend Biotech

$27.87

0.19+0.69%

At Close 4:00 PM

82.56

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Legend Biotech Corporation (LEGN) stock surged +0.69%, trading at $27.87 on NASDAQ, up from the previous close of $27.68. The stock opened at $27.78, fluctuating between $27.27 and $28.33 in the recent session.

Stock Snapshot

27.68

Prev. Close

5.15B

Market Cap

27.265

Day Low

-40.99

P/E Ratio

-0.68

EPS (TTM)

-2.38

Cash Flow per Share

27.78

Open

184.94M

Number of Shares

28.33

Day High

88.61%

Free Float in %

6.88

Book Value

1.16M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jul 08, 2026	27.51	28.44	27.27	27.87	1.16M
Jul 07, 2026	28.21	28.50	27.38	27.68	1.17M
Jul 06, 2026	29.81	29.83	27.56	28.04	1.5M
Jul 02, 2026	30.07	30.27	29.56	29.91	1.41M
Jul 01, 2026	28.75	30.25	28.75	29.89	1.62M
Jun 30, 2026	29.39	29.78	28.78	28.88	1.02M
Jun 29, 2026	29.20	29.41	27.77	29.39	1.29M
Jun 26, 2026	28.08	29.32	27.89	28.69	2.83M
Jun 25, 2026	29.25	29.98	28.13	28.43	2.62M
Jun 24, 2026	29.79	30.34	29.03	29.38	2.08M
Jun 23, 2026	28.93	30.15	28.46	29.30	2.09M
Jun 22, 2026	28.38	29.46	28.10	29.34	3.66M
Jun 18, 2026	29.66	29.80	27.43	27.93	13.59M
Jun 17, 2026	33.71	34.06	32.22	33.52	1.02M
Jun 16, 2026	35.01	35.23	33.11	33.38	2.01M
Jun 15, 2026	35.42	36.18	34.81	35.48	1.45M
Jun 12, 2026	36.22	36.85	34.88	35.87	1.7M
Jun 11, 2026	34.89	36.29	34.44	36.28	1.98M
Jun 10, 2026	32.87	35.09	32.67	34.86	1.91M
Jun 09, 2026	31.78	33.53	31.34	33.49	2.58M

Contact Details

Somerset, NJ 08873

United States

https://www.legendbiotech.com 732 317 5050

About Company

Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.

Stock Peers

ARGX

-4.64-0.50%

argenx SE$915.30 REGN

-13.35-1.97%

Regeneron Pharmaceuticals, Inc.$662.88 MDGL

20.04+3.67%

Madrigal Pharmaceuticals, Inc.$565.40 UTHR

-9.36-1.66%

United Therapeutics Corporation$554.34 VRTX

-23.82-4.56%

Vertex Pharmaceuticals Incorporated$498.43 KRYS

6.8+1.84%

Krystal Biotech, Inc.$375.40 PRAX

9.04+2.79%

Praxis Precision Medicines, Inc.$332.99 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ALNY

1.91+0.59%

Alnylam Pharmaceuticals, Inc.$323.50 LGND

-4.55-1.42%

Ligand Pharmaceuticals Incorporated$314.88

Company Overview

Legend Biotech Corporation (NASDAQ:LEGN) closed at $27.87 USD, gaining $0.19 (0.69%) from the previous close of $27.68. The stock is currently mid-range between its 52-week high and low $16.24 and $45.30. With a market capitalization of about $5.15 billion, Legend Biotech Corporation is classified as a mid-cap and shows lower-than-market volatility (beta ~0.34). Key stats such as the average daily volume over the past year has been around 2.74 million shares, volume is running light vs its 52-week average. Headquartered in Somerset, NJ, Legend Biotech Corporation operates in the Healthcare sector and the Biotechnology industry. Led by CEO Ying Huang, the company employs approximately 2,900 people and listed since June 05, 2020. Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe.

Technical Performance

LEGN has shown mixed momentum, losing -1.18% over the past week and -26.72% over the past quarter, though year-to-date performance is up 7.73%. Short-term trend indicators are bullishly aligned (SMA20 7.13%, SMA50 -4.37%, SMA200 -36.05%). The stock’s 14-day RSI is 51.3 (neutral), while the ATR of 1.08 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -57.44% below its high and over 18.72% above its low. Average 10-day trading volume of 1.31 million shares is below the 3-month average of 2.57 million, indicating normal recent market interest.

Valuation Metrics

Legend Biotech Corporation trades at a P/E ratio of -20.33, slightly below the S&P 500 average, with a price-to-sales ratio of 4.49 and a price-to-book ratio of 5.28 trading at moderately above to book value. The P/FCF stands at -21.64, also above market averages.

Dividend & Fair Value

Legend Biotech Corporation last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$65.25. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Legend Biotech Corporation generated EPS of -$1.31 over the past year. Five-year average earnings growth is 0.82%. The latest quarter delivered EPS of -$0.15. The next quarter is forecast at $0.00. Next year's EPS is expected at $20.33. Analyst sentiment is bullish. Analyst rating data shows there are 19 Strong Buy ratings, 9 Buy ratings, 2 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $90.00 to $21.00. The high target offers 222.93% upside. The low target suggests -24.65% downside. The mean target is $64.10. This offers 130.0% upside. Legend Biotech Corporation earnings surprise history is a mixed track record. The quarter that ended May 12, 2026, missed forecasts by 650.0%. The prior quarter beat by -52.94%. Over the last six quarters, Apple has recorded several small beats. These include -61.54% in March 11, 2025.

Shareholding & Insider Activity

Legend Biotech Corporation has 184.57 million shares outstanding. The public float is 162.77 million shares, elevated short interest at 8.15% of float. This equals 7.82 million shares. The short ratio is 5.53 days. Institutional investors hold 48.12% of the float. Insiders own 1.3%. Over the past six months, insider transactions show net selling. They sold 21.50 thousand shares across 3 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Legend Biotech generated $285.14M in revenue, or $1.62 per share. Gross margin was 42.25%, operating margin -155.09%, and net profit margin -181.75%. Returns are negative, with ROA at -28.03% and ROE at -41.41%.
On valuation metrics, Legend Biotech trades at a P/E of -20.33, P/S of 4.49 and P/B of 5.28. The current ratio is 2.13 and quick ratio is 2.05. Operationally, the company’s inventory turnover is 13.82 and cash conversion cycle is 33.32 days. Debt-to-equity is 0.40, supported by a cash flow-to-debt ratio of -0.45.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Legend Biotech posted revenue of $285.14M, down slightly from $117.01M in the prior quarter. Gross profit was $120.48M (margin 42.25%). Operating income was - $442.22M (margin -155.1%). Net income was- $518.25M (EPS - $2.94).
The company ended the quarter with $1.31B in cash and short-term investments, a total debt of $328.67M, and net debt of - $949.40M. Total assets were $1.85B, with equity of $1.25B. Financials further reflected weakness, with operating cash flow of - $384.47M, free cash flow of - $505.97M, and capital expenditures of - $121.51M.

Price Forecast & Outlook

Our AI price prediction model suggests that Legend Biotech Corporation stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -4.52%, with price expected at $26.61 by July 22, 2026, within a range of $23.99 to $29.38 3-Month Outlook: Projected rise of 204.7%, reaching $84.92 by October 06, 2026, with a range of $84.43 to $87.80. 1-Year Outlook: Projected loss of -49.87%, with price at $13.97 by July 08, 2027, within a range of $11.76 to $16.32.

Key Takeaways

Legend Biotech Corporation (NASDAQ:LEGN) shares are flat 7.73% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Legend Biotech Corporation trading at a premium to the broader market with a P/E of -20.33. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $71.52, suggesting 156.62% upside. Our AI forecast model points to short-term weakness (-4.52% over two weeks), a medium-term rise (204.7% over three months), and a longer-term loss (-49.87% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Legend Biotech Corporation (LEGN) stock price?

Legend Biotech Corporation (NASDAQ: LEGN) stock price is $27.87 in the last trading session. During the trading session, LEGN stock reached the peak price of $28.33 while $27.27 was the lowest point it dropped to. The percentage change in LEGN stock occurred in the recent session was 0.69% while the dollar amount for the price change in LEGN stock was $0.19.

LEGN's industry and sector of operation?

The NASDAQ listed LEGN is part of Biotechnology industry that operates in the broader Healthcare sector. Legend Biotech Corporation designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of LEGN?

Ms. Liz Gosen
Senior Vice President of Technical Operations
Dr. Ying Huang Ph.D.
Chief Executive Officer & Director
Mr. Alan Kick
Senior Vice President of Global Quality
Ms. Lori A. Macomber C.P.A.
Chief Financial Officer
Dr. Yuhong Qiu Ph.D.
Senior Vice President of Global Regulatory Affairs
Dr. Guowei Fang Ph.D.
Senior Vice President & Global Head of Research and Early Devel.
Mr. Marc Harrison
Vice President & Gen. Counsel
Ms. Lori A. Macomber CPA
Chief Financial Officer
Mr. Steven J. Gavel
Senior Vice President of Commercial Devel., US & Europe
Joanne Choi
Senior Mang. of Investor Relations
Ms. Elaine Qian
Vice President & Global Head of HR
Deborah Wong
Executive Director of Strategic Marketing & Corporation Communications

How LEGN did perform over past 52-week?

LEGN's closing price is 71.61% higher than its 52-week low of $16.24 where as its distance from 52-week high of $45.30 is -38.47%.

How many employees does LEGN have?

Number of LEGN employees currently stands at 2,900.

Link for LEGN official website?

Official Website of LEGN is: https://www.legendbiotech.com

How do I contact LEGN?

LEGN could be contacted at phone 732 317 5050 and can also be accessed through its website. LEGN operates from 2101 Cottontail Lane, Somerset, NJ 08873, United States.

How many shares of LEGN are traded daily?

LEGN stock volume for the day was 1.16M shares. The average number of LEGN shares traded daily for last 3 months was 2.74M.

What is the market cap of LEGN currently?

The market value of LEGN currently stands at $5.15B with its latest stock price at $27.87 and 184.94M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	2900
Beta	0.35
Sales or Revenue	$285.14M
5Y Sales Change%	2.296%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

LEGN Company Profile and Key Details

Legend Biotech

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Dividend & Fair Value

Company Overview

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Earnings & Analyst Outlook

Valuation Metrics

Key Takeaways

Price Forecast & Outlook